SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 260 filers reported holding SAGE THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 2.05 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,601 | -56.2% | 175 | 0.0% | 0.00% | – |
| Q2 2023 | $8,228 | +12.1% | 175 | 0.0% | 0.00% | – |
| Q1 2023 | $7,343 | +104800.0% | 175 | -5.4% | 0.00% | – |
| Q4 2022 | $7 | -99.9% | 185 | 0.0% | 0.00% | – |
| Q3 2022 | $7,000 | +40.0% | 185 | +5.7% | 0.00% | – |
| Q2 2022 | $5,000 | -16.7% | 175 | -9.8% | 0.00% | – |
| Q1 2022 | $6,000 | -14.3% | 194 | +10.9% | 0.00% | – |
| Q4 2021 | $7,000 | 0.0% | 175 | 0.0% | 0.00% | – |
| Q3 2021 | $7,000 | -30.0% | 175 | 0.0% | 0.00% | – |
| Q2 2021 | $10,000 | -23.1% | 175 | 0.0% | 0.00% | – |
| Q1 2021 | $13,000 | -13.3% | 175 | 0.0% | 0.00% | – |
| Q4 2020 | $15,000 | +36.4% | 175 | 0.0% | 0.00% | – |
| Q3 2020 | $11,000 | +57.1% | 175 | 0.0% | 0.00% | – |
| Q2 2020 | $7,000 | +40.0% | 175 | 0.0% | 0.00% | – |
| Q1 2020 | $5,000 | -66.7% | 175 | -14.6% | 0.00% | -100.0% |
| Q4 2019 | $15,000 | – | 205 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sio Capital Management, LLC | 179,200 | $29,516,000 | 16.65% |
| TRV GP II, LLC | 547,916 | $90,247,000 | 16.25% |
| Opus Point Partners Management, LLC | 71,000 | $11,694,000 | 10.12% |
| Casdin Capital, LLC | 250,000 | $41,178,000 | 10.03% |
| RA Capital Management | 455,173 | $74,972,000 | 6.27% |
| Crawford Lake Capital Management, LLC | 154,278 | $25,411,000 | 6.00% |
| Palo Alto Investors LP | 810,806 | $133,548,000 | 5.75% |
| GREAT POINT PARTNERS LLC | 200,000 | $32,942,000 | 5.62% |
| BB BIOTECH AG | 1,042,439 | $171,700,000 | 4.84% |
| Crawford Lake Capital Management, LLC | 92,300 | $15,203,000 | 3.59% |